Adjunct Faculty
Adjunct faculty typically have an academic or research appointment at another institution and contribute or collaborate with one or more School of Medicine faculty members or programs.
Adjunct rank detailsLuca Fabris, MD, PhD, FAASLD
Associate Professor Adjunct of Medicine (Digestive Diseases), Internal MedicineAbout
Research
Publications
2025
Cholangiocarcinoma 2026: status quo, unmet needs and priorities
Banales J, Rodrigues P, Affò S, Andersen J, Aspichueta P, Boulter L, Bridgewater J, Calvisi D, Cardenas A, Cardinale V, Carpino G, Coulouarn C, Dopazo C, Edeline J, Fabris L, Folseraas T, Forner A, Goeppert B, Heikenwalder M, Kendall T, Khan S, Klümpen H, Koerkamp B, Lamarca A, Lindsey S, Lleo A, Luedde T, Macias R, Morement H, Nault J, Olaizola P, Perugorria M, Raggi C, Rimassa L, Saborowski A, Valle J, Vithayathil M, Vogel A, Braconi C. Cholangiocarcinoma 2026: status quo, unmet needs and priorities. Nature Reviews Gastroenterology & Hepatology 2025, 23: 65-96. PMID: 41372578, DOI: 10.1038/s41575-025-01153-w.Peer-Reviewed Original ResearchConceptsRisk factorsOverall well-beingCurative surgical interventionInternational consensus statementPatient outcomesRare neoplasmsSurvival improvementSurgical interventionConsensus statementPoor prognosisResearch prioritiesWell-beingClinical managementPanel questionnaireBile ductConsensus recommendationsCholangiocarcinomaTherapeutic approachesEffective treatmentInternational expertsNovel biomarkersTherapeutic targetCancer-associated thrombosis in cholangiocarcinoma: Exploring a phenotype of tumor aggressiveness
Fabris L, Frión-Herrera Y, Cadamuro M, Campello E, Simioni P. Cancer-associated thrombosis in cholangiocarcinoma: Exploring a phenotype of tumor aggressiveness. Biochimica Et Biophysica Acta (BBA) - Reviews On Cancer 2025, 1880: 189457. PMID: 40987389, DOI: 10.1016/j.bbcan.2025.189457.Peer-Reviewed Original ResearchVenous thromboembolismPrognostic factorsPhenotypes of tumor aggressivenessOccurrence of venous thromboembolismRisk of bleedingSubgroup of patientsCancer-associated thrombosisCancer-related morbidityLiver malignanciesTumor aggressivenessHypercoagulable stateTumor progressionWorse outcomesClinical significanceCholangiocarcinomaTreatment approachesCancer typesPrediction scoreRiskMalignancyThromboprophylaxisBleedingCase Report: jaundice in the young: the complexity of rare diseases beyond cholangiopathies
Guglielmo S, Pasin F, Biolo M, Mescoli C, Vio S, Fabris L, Simioni P. Case Report: jaundice in the young: the complexity of rare diseases beyond cholangiopathies. Frontiers In Gastroenterology 2025, 4: 1579928. PMID: 41822259, PMCID: PMC12952453, DOI: 10.3389/fgstr.2025.1579928.Peer-Reviewed Original ResearchAutoimmune hemolytic anemiaInflammatory bowel diseaseSerum IgG4 levelsAutoimmune pancreatitisCorticosteroid therapyIgG4 levelsClinical presentationAssociated with elevated serum IgG4 levelsDiagnosis of type 2 AIPComplication of autoimmune pancreatitisSuspicion of autoimmune pancreatitisElevated serum IgG4 levelsRemission of jaundiceType 2 AIPAssociated with inflammatory bowel diseaseBile duct dilatationPositive Coombs testDiagnosis of Crohn's diseaseMild weight lossPancreato-biliary diseasesPresentation of diseasePale stoolsAbdominal painClinical responseUnnecessary surgeryTHU-125 Activation of coagulation system and platelet aggregation in patients with primary sclerosing cholangitis and cholangiocarcinoma
Frion-Herrera Y, Venturin C, Cadamuro M, Nuozzi G, Radu C, Mescoli C, Cillo U, Gringeri E, Campello E, Strazzabosco M, Cigliano A, Calvisi D, Simioni P, Fabris L. THU-125 Activation of coagulation system and platelet aggregation in patients with primary sclerosing cholangitis and cholangiocarcinoma. Journal Of Hepatology 2025, 82: s446-s447. DOI: 10.1016/s0168-8278(25)01271-1.Peer-Reviewed Original ResearchOncostatin M modulates the biology of cholangiocarcinoma cells and the tumor microenvironment
Porro N, Nurcis J, De Siervi S, Cadamuro M, Turato C, Mantovani S, Oliviero B, Fabris L, Mondelli M, Marra F, Parola M, Caligiuri A, Pastore M, Cannito S, Gentilini A. Oncostatin M modulates the biology of cholangiocarcinoma cells and the tumor microenvironment. Digestive And Liver Disease 2025, 57: s18. DOI: 10.1016/j.dld.2025.01.031.Peer-Reviewed Original ResearchTumor microenvironmentOncostatin MStromal cellsFibrotic tumor microenvironmentPrimary hepatic stellate cellsCultured stromal cellsHuman iCCA cell linesResistance to chemotherapyCell migrationTumor-stroma interactionsDose-dependent increaseExpression of oncostatin MCancer-associated fibroblastsHepatic stellate cellsOncostatin M receptorAggressive tumorsInvasion of iCCA cellsHuman CCA specimensPoor prognosisPeritumoral tissuesCancer-associated pathwaysIncreased cell migrationConditioned mediumTumorCancer cells
2024
Noninvasive Assessment of Portal Hypertension in Patients With Primary Biliary Cholangitis Is Affected by Severity of Cholestasis
Calvaruso V, Celsa C, Cristoferi L, Scaravaglio M, Smith R, Kaur S, Di Maria G, Capodicasa L, Pennisi G, Gerussi A, Nofit E, Malinverno F, Lampertico P, Cazzagon N, Marzioni M, Vespasiani-Gentilucci U, Colapietro F, Andreone P, Lleo A, Rigamonti C, Viganò M, Giannini E, Russello M, Vanni E, Cerini F, Orlandini A, Brunetto M, Niro G, Vettori G, Castellaneta A, Cardinale V, Alvaro D, Mega A, Palitti V, Cossiga V, Morisco F, Bellanti F, Baiocchi L, Fabris L, Persico M, Degasperi E, Labanca S, Bonaiuto E, Pezzato F, Federico A, Petta S, Di Marco V, Mells G, Culver E, Invernizzi P, Cammà C, Carbone M. Noninvasive Assessment of Portal Hypertension in Patients With Primary Biliary Cholangitis Is Affected by Severity of Cholestasis. Clinical Gastroenterology And Hepatology 2024, 23: 1766-1775.e7. PMID: 39674236, DOI: 10.1016/j.cgh.2024.10.020.Peer-Reviewed Original ResearchConceptsCompensated advanced chronic liver diseaseClinically Significant Portal HypertensionHigh-risk varicesPrimary biliary cholangitisBaveno VIDecision curve analysisNoninvasive testsAlkaline phosphatase levelsSeverity of cholestasisBiliary cholangitisEsophageal varicesPortal hypertensionAdvanced chronic liver diseaseNoninvasive assessmentLow riskCurve analysisInfluence of cholestasisSignificant portal hypertensionAbstractText Label="Background &Alkaline phosphataseRisk of clinically significant portal hypertensionAssessment of portal hypertensionChronic liver diseaseConsecutive patientsUpper endoscopyEditor's Note: Low-Dose Paclitaxel Reduces S100A4 Nuclear Import to Inhibit Invasion and Hematogenous Metastasis of Cholangiocarcinoma.
Cadamuro M, Spagnuolo G, Sambado L, Indraccolo S, Nardo G, Rosato A, Brivio S, Caslini C, Stecca T, Massani M, Bassi N, Novelli E, Spirli C, Fabris L, Strazzabosco M. Editor's Note: Low-Dose Paclitaxel Reduces S100A4 Nuclear Import to Inhibit Invasion and Hematogenous Metastasis of Cholangiocarcinoma. Cancer Research 2024, 84: 3909. PMID: 39544086, DOI: 10.1158/0008-5472.can-24-3017.Peer-Reviewed Original ResearchLiver-related aspects of valoctocogene roxaparvovec gene therapy for hemophilia A: expert guidance for clinical practice
La Mura V, Cardinale V, De Cristofaro R, De Santis A, Di Minno G, Fabris L, Marra F, Morisco F, Peyvandi F, Pompili M, Santoro C, Zanon E, Castaman G. Liver-related aspects of valoctocogene roxaparvovec gene therapy for hemophilia A: expert guidance for clinical practice. Blood Advances 2024, 8: 5725-5734. PMID: 39226466, PMCID: PMC11599981, DOI: 10.1182/bloodadvances.2024013750.Peer-Reviewed Original ResearchConceptsAlanine aminotransferase elevationGene therapyTransient elastographyAlanine aminotransferaseAbdominal ultrasoundVirus-based gene therapyPretreatment assessmentAlanine aminotransferase monitoringLiver-related effectsAbnormal liver enzymesLiver stiffness measurementRisk of hepatotoxicityAlanine aminotransferase levelsRisk of liver damageReturn to baselineHepatic sequelaeValoctocogene roxaparvovecImmunosuppressive therapyAutoimmune hepatitisHemophilia ALiver stiffnessTreatment eligibilityClinical managementLiver healthLiver functionAnticoagulants in cirrhosis: main concerns
Campello E, Fabris L, Simioni P. Anticoagulants in cirrhosis: main concerns. Nature Reviews Gastroenterology & Hepatology 2024, 21: 827-828. PMID: 39394378, DOI: 10.1038/s41575-024-00998-x.Peer-Reviewed Original ResearchMachine learning application to histology for the study of cholangiopathies (BiliQML): A chance to put liver biopsy back to its former glory?
Venturin C, Fabris L. Machine learning application to histology for the study of cholangiopathies (BiliQML): A chance to put liver biopsy back to its former glory? AJP Gastrointestinal And Liver Physiology 2024, 327: g733-g736. PMID: 39378378, DOI: 10.1152/ajpgi.00173.2024.Peer-Reviewed Original Research